Search Results - "Sawant Basak, Aarti"

Prescription of Oral Contraceptives by Licensed Pharmacists in the USA by Sawant‐Basak, Aarti, Ingle‐Jadhav, Priyanka

Get full text

Investigation of CYP3A induction by PF‐05251749 in early clinical development: comparison of linear slope physiologically based pharmacokinetic prediction and biomarker response by Lin, Jian, Gaudreault, Francois, Johnson, Nathaniel, Lin, Zhiwu, Nouri, Parya, Goosen, Theunis C., Sawant‐Basak, Aarti

“…PF‐05251749 is a dual inhibitor of casein kinase 1 δ/ε under clinical development to treat disruption of circadian rhythm in Alzheimer's and Parkinson's…”
Get full text

Investigating CNS distribution of PF‐05212377, a P‐glycoprotein substrate, by translation of 5‐HT6 receptor occupancy from non‐human primates to humans by Sawant‐Basak, Aarti, Chen, Laigao, Lockwood, Peter, Boyden, Tracey, Doran, Angela C., Mancuso, Jessica, Zasadny, Kenneth, McCarthy, Timothy, Morris, Evan D., Carson, Richard E., Esterlis, Irina, Huang, Yiyun, Nabulsi, Nabeel, Planeta, Beata, Fullerton, Terence

“…PF‐05212377 (SAM760) is a potent and selective 5‐HT6 antagonist, previously under development for the treatment of Alzheimer’s disease. In vitro, PF‐05212377…”
Get full text

Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants by Sawant‐Basak, Aarti, Bergman, Arthur J., Mancuso, Jessica, Tripathy, Sakambari, Gosset, James R., Mendes da Costa, Laure, Esler, William P., Calle, Roberto A.

“…Co‐administration of clesacostat (acetyl‐CoA carboxylase inhibitor, PF‐05221304) and ervogastat (diacylglycerol O‐acyltransferase inhibitor, PF‐06865571) in…”
Get full text

Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White Paper by Sawant‐Basak, Aarti, Urva, Shweta, Mukker, Jatinder Kaur, Haertter, Sebastian, Mariano, Dean, Parasrampuria, Dolly A., Goteti, Kosalaram, Singh, Ravi Shankar Prasad, Chiney, Manoj, Liao, Michael Z., Chang, Sandy S., Mehta, Rashmi

“…The 2022 United States Food and Drug Administration (US FDA) draft guidance on diversity plan (DP), which will be implemented through the Diversity Action…”
Get full text

Investigating CNS distribution of PF-05212377, a P-glycoprotein substrate, by translation of 5-HT 6 receptor occupancy from non-human primates to humans by Sawant-Basak, Aarti, Chen, Laigao, Lockwood, Peter, Boyden, Tracey, Doran, Angela C, Mancuso, Jessica, Zasadny, Kenneth, McCarthy, Timothy, Morris, Evan D, Carson, Richard E, Esterlis, Irina, Huang, Yiyun, Nabulsi, Nabeel, Planeta, Beata, Fullerton, Terence

“…PF-05212377 (SAM760) is a potent and selective 5-HT antagonist, previously under development for the treatment of Alzheimer's disease. In vitro, PF-05212377…”
Get full text

Design and Discovery of a Selective Small Molecule κ Opioid Antagonist (2-Methyl-N-((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242) by Verhoest, Patrick R, Sawant Basak, Aarti, Parikh, Vinod, Hayward, Matthew, Kauffman, Gregory W, Paradis, Vanessa, McHardy, Stanton F, McLean, Stafford, Grimwood, Sarah, Schmidt, Anne W, Vanase-Frawley, Michelle, Freeman, Jodi, Van Deusen, Jeffrey, Cox, Loretta, Wong, Diane, Liras, Spiros

“…By use of parallel chemistry coupled with physicochemical property design, a series of selective κ opioid antagonists have been discovered. The parallel…”
Get full text

Identification of Multiple 5‑HT4 Partial Agonist Clinical Candidates for the Treatment of Alzheimer’s Disease by Brodney, Michael A, Johnson, David E, Sawant-Basak, Aarti, Coffman, Karen J, Drummond, Elena M, Hudson, Emily L, Fisher, Katherine E, Noguchi, Hirohide, Waizumi, Nobuaki, McDowell, Laura L, Papanikolaou, Alexandros, Pettersen, Betty A, Schmidt, Anne W, Tseng, Elaine, Stutzman-Engwall, Kim, Rubitski, David M, Vanase-Frawley, Michelle A, Grimwood, Sarah

“…The cognitive impairments observed in Alzheimer’s disease (AD) are in part a consequence of reduced acetylcholine (ACh) levels resulting from a loss of…”
Get full text

Metabolism of a serotonin-4 receptor partial agonist 4-{4-[4-tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-piperidin-1-ylmethyl}-tetrahydropyran-4-ol (TBPT): identification of an unusual pharmacologically active cyclized oxazolidine metabolite in human by Sawant-Basak, Aarti, Coffman, Karen J, Walker, Gregory S, Ryder, Tim F, Tseng, Elaine, Miller, Emily, Lee, Carlos, Vanase-Frawley, Michelle A, Wong, John W, Brodney, Michael A, Rapp, Tracey, Obach, R Scott

“…4-{4-[4-Tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-piperidin-1-ylmethyl}-tetrahydropyran-4-ol (PF-4995274, TBPT) is a new agent that is a partial…”
Get more information

Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology by Maurer, Tristan S., Ghosh, Avijit, Haddish-Berhane, Nahor, Sawant-Basak, Aarti, Boustany-Kari, Carine M., She, Li, Leininger, Michael T., Zhu, Tong, Tugnait, Meera, Yang, Xin, Kimoto, Emi, Mascitti, Vincent, Robinson, Ralph P.

“…ABSTRACT Sodium–glucose co-transporter-2 (SGLT2) inhibitors are an emerging class of agents for use in the treatment of type 2 diabetes mellitus (T2DM)…”
Get full text

Investigation of metabolism and disposition of Pf-05212377: Unexpected sulfonamide hydrolysis explains the lack of ketoconazole mediated DDI by Sawant-Basak, Aarti, Obach, R. Scott, Doran, Angela C., Gao, Hongying, Schildknegt, Klaas, Lockwood, Peter, Mancuso, Jessica, Tse, Susanna, Comery, Thomas

Get full text

Metabolism and clinical pharmacokinetics of 2-methyl-n-(2′-(pyrrolidinyl-1-ylsulfonyl)-n-[1,1′-biphenyl]-4-yl)propran-1-amine: insights into monoamine oxidase- and CYP-mediated disposition by integration of in vitro ADME tools by Sawant Basak, Aarti, Byon, Wonkyung, Tseng-Lovering, Elaine, Funk, Carrie, Wood, Linda, Lin, Chang, Delnomdedieu, Marielle, Verhoest, Patrick, Parikh, Vinod, Cox, Loretta M., Miller, Emily, Gao, Hongying, Obach, Ronald S.

“…Abstract 1. In early discovery stages, 2-methyl-N-(2′-(pyrrolidinyl-1-ylsulfonyl)-[1,1′-biphenyl]-4-yl)propan-1-amine (PBPA) demonstrated monoamine oxidase A…”
Get full text

Emerging Models of Drug Metabolism, Transporters, and Toxicity by Sawant-Basak, Aarti, Obach, R Scott

“…This commentary summarizes expert mini-reviews and original research articles that have been assembled in a special issue on novel models of drug metabolism…”
Get full text

Assessing Trends in Cytokine–CYP Drug Interactions and Relevance to Drug Dosing by Sawant-Basak, Aarti, Olabode, Damilola, Dai, David, Vishwanathan, Karthick, Phipps, Alex

“…The regulation of drug-metabolizing enzymes and transporters by cytokines has been extensively studied in vitro and in clinic. Cytokine-mediated suppression of…”
Get full text

Physiologically Relevant, Humanized Intestinal Systems to Study Metabolism and Transport of Small Molecule Therapeutics by Sawant-Basak, Aarti, Rodrigues, A David, Lech, Matthew, Doyonnas, Regis, Kasaian, Marion, Prasad, Bhagwat, Tsamandouras, Nikolaos

“…Intestinal disposition of small molecules involves interplay of drug metabolizing enzymes (DMEs), transporters, and host-microbiome interactions, which has…”
Get full text

Assessing trends in cytokine-CYP drug interaction and relevance to drug dosing by Sawant-Basak, Aarti, Olabode, Damilola, Dai, David, Vishwanathan, Karthick, Phipps, Alex

“…The regulation of drug-metabolizing enzymes and transporters by cytokines has been extensively studied, in vitro and in clinic. Cytokine-mediated suppression…”
Get full text

F30. QUINTUPLE HYPOTHESES TARGETED IN SCHIZOPHRENIA: FIGHT FIRE WITH FIRE by Koola, Maju, Sklar, Jennifer, Davis, Whitney, Nikiforuk, Agnieszka, Meissen, John, Sawant-Basak, Aarti, Aaronson, Scott, Kozak, Rouba

“…Abstract Background There are no effective treatments available or on the horizon for cognitive impairments associated with schizophrenia (CIAS) and primary…”
Get full text

Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments by Koola, Maju Mathew, Sklar, Jennifer, Davis, Whitney, Nikiforuk, Agnieszka, Meissen, John K., Sawant-Basak, Aarti, Aaronson, Scott T., Kozak, Rouba

Get full text

Determination of receptor occupancy in the presence of mass dose: [ 11 C]GSK189254 PET imaging of histamine H 3 receptor occupancy by PF-03654746 by Gallezot, Jean-Dominique, Planeta, Beata, Nabulsi, Nabeel, Palumbo, Donna, Li, Xiaoxi, Liu, Jing, Rowinski, Carolyn, Chidsey, Kristin, Labaree, David, Ropchan, Jim, Lin, Shu-Fei, Sawant-Basak, Aarti, McCarthy, Timothy J, Schmidt, Anne W, Huang, Yiyun, Carson, Richard E

“…Measurements of drug occupancies using positron emission tomography (PET) can be biased if the radioligand concentration exceeds "tracer" levels. Negative bias…”
Get full text

Estimation of Circulating Drug Metabolite Exposure in Human Using In Vitro Data and Physiologically Based Pharmacokinetic Modeling: Example of a High Metabolite/Parent Drug Ratio by Obach, R Scott, Lin, Jian, Kimoto, Emi, Duvvuri, Sridhar, Nicholas, Timothy, Kadar, Eugene P, Tremaine, Larry M, Sawant-Basak, Aarti

“…( )-4-((4-(((4-((tetrahydrofuran-3-yl)oxy)benzo[d]isoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol (TBPT), a serotonin-4 receptor…”
Get full text